7148.KLSE Duopharma Biotech Bhd

Healthcare Pharmaceuticals Kuala Lumpur Exchange
Add to portfolio Ask AI about 7148.KLSE
1.12 MYR
Close of Oct 29, 2026
1.08 1.50
Market cap
MYR 1.08B
P/E
10.2x
P/B
1.37x
ROE
15.4%
Dividend yield
3.13%
Fundamental score
3.4/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 7148.KLSE undervalued?

Graham number
Price1.12
Graham value1.42
Discount21.2%

7148.KLSE trades 21.2% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Duopharma Biotech Bhd fundamental analysis

17 of 22 checks passed

ROE 1/2

Moderate return on equity (15.4%), between 10% and 20%.

ROA 1/1

Return on assets (8.3%) is above the industry median (5.5%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (39.6%) is above the 5-year average (7.5% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (39.6%) is above the industry median (15.6%).

Revenue Growth 2/2

Revenue grew 10.2% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (60.0%), up to 100%.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 1/1

EBIT is 7.7x against interest expense, well covered.

PE vs Market 1/1

PE (10.2x) is below the market median (11.4x).

PE vs Industry 1/1

PE (10.2x) is below the industry median (16.6x).

PBV 0/1

Price to book (1.4x) is above the industry median (0.9x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 14.0, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 1.37, above 1.

Dividend Yield 1/2

Dividend yield (3.1%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 38.5%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

About Duopharma Biotech Bhd

Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives under the Uphamol, Uphacol, and Uphaplast brand names; eyecare products under t…

Full company profile